Neuroendocrine tumors (NETs) of the breast represent 1% of breast carcinomas. Histopathological misinterpretation of breast NET is common. We present the case of a female patient who had a breast mass diagnosed as invasive ductal carcinoma initially by histopathological examination. Fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) revealed 2 ametabolic hypodense liver lesions. Subsequently, the patient underwent fibroblast activation protein inhibitor (FAPI)-PET/CT, which did not reveal any FAP expression in the liver lesions, but increased FAP expression was observed in the soft tissue mass of the mesenteric root. Consequently, the pathology of the biopsy taken from the nodule in the right breast was revised, and a diagnosis of grade 2 NET was established. The benefit of FAPI-PET/CT on NETs has been previously investigated. Further prospective studies are required to establish the role of FAPI-PET/CT in NET management
展开▼
机译：乳腺神经内分泌肿瘤 （NETs） 占乳腺癌的 1%。乳腺 NET 的组织病理学误解很常见。我们介绍了一名女性患者的病例，该患者的乳腺肿块最初通过组织病理学检查诊断为浸润性导管癌。氟代脱氧葡萄糖正电子发射断层扫描/计算机断层扫描 （FDG PET/CT） 显示 2 个无代谢的低密度肝脏病变。随后，患者接受了成纤维细胞活化蛋白抑制剂 （FAPI）-PET/CT，在肝脏病灶中未显示任何 FAP 表达，但在肠系膜根的软组织块中观察到 FAP 表达增加。因此，从右乳房结节采集的活检的病理学被修正，并确定了 2 级 NET 的诊断。FAPI-PET/CT 对 NET 的益处先前已研究过。需要进一步的前瞻性研究来确定 FAPI-PET/CT 在 NET 管理中的作用
展开▼
